Aileron Therapeutics at ASCO 2017 Annual Meeting
June 3, 2017 at 3:39 PM EDT
Oral Abstract Session: “Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas”
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Abstract #:2505